Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Income Before Tax

Profit after all operating and non-operating items but before income tax.

Seer, Inc.NASDAQ: SEER

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$16.83M, compared with -$19.85M a year earlier. Trailing-twelve-month income before tax was -$70.38M.

Context

  • Income before tax amounted to 455.4% of revenue in FY2025, down 164.9 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$16.83M or moves back toward the trailing-twelve-month quarterly average of -$17.59M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$16.83M-5.4% QoQ
Last fiscal yearDec 2025
-$73.4M+15.1% YoY
LTMMar 2026
-$70.38M+17.8% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.2%——
1 year+15.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(73.4M) USD
Year-over-year change
+15.1%

Income Before Tax vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +17.8% is the 6th highest of 19, against a peer median of -2.5%.
  • Income before tax amounts to 468.0% of revenue for SEER, versus a peer median of 307.0%.
SEER Competitors
Income Before Tax for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$308.21M USD+226.3%—43.9%
MNOVMediciNova, Inc.LTM Mar 2026-$11.71M USD-5.0%—1963.3%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026-$34.55M USD+23.8%——
STTKShattuck Labs, Inc.LTM Mar 2026-$49.87M USD+29.4%—4987.4%
SEERSeer, Inc.LTM Mar 2026-$70.38M USD+17.8%—468.0%
MOLNMolecular Partners AGLTM Mar 2026-CHF 72.05M CHF-17.4%——
FHTXFoghorn Therapeutics Inc.LTM Mar 2026-$75.32M USD+6.4%—266.9%
PEPGPepGen Inc.LTM Mar 2026-$77.15M USD+24.9%——
NKTXNkarta, Inc.LTM Mar 2026-$99.93M USD+10.2%——
CCCCC4 Therapeutics, Inc.LTM Mar 2026-$103.68M USD-0.5%—297.4%
QSIQuantum-Si incorporatedLTM Mar 2026-$103.9M USD-3.2%—5609.9%
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026-$131.88M USD-1493.8%—307.0%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026-$135.21M USD-1.8%——
PHVSPharvaris N.V.LTM Sep 2026-€179.08M EUR-8.9%——
CGEMCullinan Therapeutics, Inc.LTM Mar 2026-$221.04M USD-23.7%——
SANASana Biotechnology, Inc.LTM Mar 2026-$241.99M USD-16.0%——
LYELLyell Immunopharma, Inc.LTM Mar 2026-$246.41M USD+26.3%—794858.1%
KYMRKymera Therapeutics, Inc.LTM Jun 2026-$299.87M USD-8.9%—285.6%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026-$349.58M USD-83.2%——
Peer median (excluding SEER) —-2.5%—307.0%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.39M14.69M15.18M13.95M16.12M
Cost of Revenue6.77M14.3M13.73M7.12M14.22M
Gross Profit(374K)384K1.45M6.83M1.9M
Gross Margin-5.8%2.6%9.5%49.0%11.8%
Research & Development29.12M45.8M47.44M50.59M37.77M
Selling, General & Admin42.2M52.63M58.95M56.57M42.58M
Operating Expenses71.32M98.43M106.39M106.93M80.35M
Depreciation & Amortization3.56M5.9M5.58M6.18M6.1M
EBITDA(67.61M)(87.07M)(80.7M)(80.33M)(67.3M)
EBITDA Margin-1057.3%-592.9%-531.5%-575.9%-417.5%
Operating Income(71.7M)(98.04M)(104.94M)(100.1M)(78.45M)
Operating Margin-1121.3%-667.6%-691.2%-717.7%-486.7%
Interest Income326K4.6M17.76M16.67M11.52M
Interest Expense22K0000
Other Income / Expenses527K5.08M18.67M13.6M5.05M
Income Before Tax(71.17M)(92.97M)(86.28M)(86.5M)(73.4M)
Pre-Tax Margin-1113.1%-633.1%-568.3%-620.2%-455.4%
Income Tax Expense00098K201K
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Net Margin-1113.1%-633.1%-568.3%-620.9%-456.6%
EPS (Basic)(1.13)(1.42)(1.35)(1.39)(1.28)
EPS (Diluted)(1.13)(1.42)(1.35)(1.39)(1.28)
Weighted Avg Shares60.86M62.43M63.85M62.35M57.45M
Weighted Avg Shares (Diluted)60.86M62.43M63.85M62.35M57.45M

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.